(R,R)-Formoterol - CAS 67346-49-0
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, [R-(R*,R*)]-;4-[(1R)-2-[[(1R)-2-(4-Methoxyphenyl)-1-methylethyl]amino]-1-hydroxyethyl]-2-(formylamino)phenol;N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(αR)-α-methyl-
CAS Number:
(R,R)-Formoterol is a long acting beta-adrenoceptor agonist acts as a novel highly β2-selective adrenergic agonist and holds promise as a β2-agonist that could impart selective beneficial metabolic effects.
Molecular Weight:
Molecular Formula:
Quality Standard:
Enterprise Standard
Canonical SMILES:
Adrenergic Receptor
Current Developer:
Mylan Specialty
Chemical Structure
CAS 67346-49-0 (R,R)-Formoterol

Related Adrenergic Receptor Products

(CAS: 1198790-53-2)

This active molecular is a SNDR (serotonin-norepinephrine-dopamine reuptake) inhibitor It was originated by Bristol-Myers Squibb for the treatment of major depr...

Moxonidine hydrochloride
(CAS: 75536-04-8)

Moxonidine hydrochloride is a mixed agonist of α2-adrenergic receptor (α2AR) and imidazoline-1 receptor(I1R). Its Ki values is 4.2±3.2 nmol/L, 13.0±4.2 nmol/L, ...

SNAP-8719 HCl
(CAS: 255893-38-0)

SNAP-8719, structurally very similar to BMY-7378, is a selective, orally active α1D-AR antagonist with lower binding affinity for the 5-HT1A receptor.

CAS 86347-14-0 Medetomidine

(CAS: 86347-14-0)

Medetomidine is a potent, highly selective α2-adrenoceptor agonist, which Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively. It is often ...

CAS 57149-07-2 Naftopidil

(CAS: 57149-07-2)

Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker with a Ki of 58.3 nM.

CAS 66711-21-5 Apraclonidine

(CAS: 66711-21-5)

Apraclonidine is a clonidine derivative with relatively selective alpha-2-adrenergic agonistic activity. It is an α2 adrenergic receptor agonist and a weak α1 a...

CAS 90038-01-0 Detomidine HCl

Detomidine HCl
(CAS: 90038-01-0)

Detomidine is a selective α2-adrenoceptor agonist (Ki = 1.62 nM) that binds to α1-adrenoceptors with much weaker potency (Ki = 415 nM).

CAS 94749-08-3 Salmeterol Xinafoate

Salmeterol Xinafoate
(CAS: 94749-08-3)

Salmeterol Xinafoate is a long-acting β2-adrenergic receptor agonist with anti-inflammatory effects, used in the treatment of asthma symptoms and chronic obstru...

(CAS: 130466-38-5)

MK-467 is a peripheral Alpha2 -adrenoceptor antagonist originated by Merck & Co. It can dose-dependently attenuate the bradycardia associated with dexmedetomidi...

Nolomirole hydrochloride
(CAS: 138531-51-8)

Nolomirole is a Alpha 2 adrenergic receptor and Dopamine D2 receptor agonist. Nolomirole can attenuate the heart failure signs in the monocrotaline-induced cong...

CAS 51781-21-6 Carteolol Hydrochloride

Carteolol Hydrochloride
(CAS: 51781-21-6)

Carteolol HCl is a β-adrenoceptor antagonist, used for the treatment of glaucoma.

CAS 59-98-3 Tolazoline

(CAS: 59-98-3)

Tolazoline is a non-selective competitive α-adrenergic receptor antagonist used in treatment of persistent pulmonary hypertension of the newborn..

CAS 104054-27-5 Atipamezole

(CAS: 104054-27-5)

Atipamezole, a 4-substituted imidazole derivative, is an alpha2-adrenoceptor blocker which could be used for animals to recover from the anesthesia by lowering ...

CAS 38363-32-5 Penbutolol sulfate

Penbutolol sulfate
(CAS: 38363-32-5)

Penbutolol is a sympathomimetic drug used to treat mild to moderate high blood pressure by binding to both beta-1 adrenergic receptors and beta-2 adrenergic rec...

CAS 81161-17-3 Esmolol HCl

Esmolol HCl
(CAS: 81161-17-3)

Esmolol is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane ...

CAS 98418-47-4 Metoprolol succinate

Metoprolol succinate
(CAS: 98418-47-4)

Metoprolol succinate is a selective β-adrenoceptor antagonist. It is used in treatment of several diseases of the cardiovascular system. It is a drug used in th...

CAS 54-80-8 Pronetalol

(CAS: 54-80-8)

Pronethalol is a non-selective beta-adrenergic blocking agentused in treatment due to carcinogenic properties.

CAS 56392-17-7 Metoprolol Tartrate

Metoprolol Tartrate
(CAS: 56392-17-7)

Metoprolol Tartrate is a cardioselective β-adrenergic receptor blocker with IC50 of 42 ng/mL.

CAS 145108-58-3 Dexmedetomidine HCl

Dexmedetomidine HCl
(CAS: 145108-58-3)

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant s...

Fenoterol hydrochloride
(CAS: 1944-10-1)

Fenoterol hydrochloride is a β2 adrenoreceptor agonist used as a bronchodilator for the treatment and prophylaxis of reversible bronchospasm, administered by in...

Reference Reading

1.The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D1, Schröder-Babo W2, Cohuet G3, Muraro A4, Bonnet-Gonod F3, Petruzzelli S4, Hoffmann M5, Siergiejko Z6; TRIDENT study investigators. Respir Med. 2016 May;114:84-90. doi: 10.1016/j.rmed.2016.03.018. Epub 2016 Mar 26.
This multicentre, double-blind, randomised, placebo-controlled, crossover study aimed to determine the dose-response of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (GB) when added to beclometasone dipropionate plus formoterol fumarate (BDP/FF) in patients with COPD. Patients received extrafine GB 12.5, 25 or 50 μg twice daily (BID) or placebo for 7 days via pressurised metered dose inhaler (pMDI), and extrafine BDP/FF via pMDI throughout the study. The primary objective was to demonstrate superiority of GB plus BDP/FF versus BDP/FF in terms of FEV1 area under the curve from 0 to 12 h (AUC0-12h) on Day 7. Secondary endpoints included: FEV1 AUC0-12h on Day 1; peak FEV1 and FVC on Days 1 and 7; and trough (12 h post-dose) FEV1, FVC and inspiratory capacity (IC) on Days 1 and 7. Of 178 patients randomised (mean age 62.7 years, post-bronchodilator FEV1 48.9%), 172 (96.6%) completed. Mean FEV1 AUC0-12h on Day 7 was significantly higher (p < 0.
2.Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study.
Fuhr R1, Leselbaum A2, Aubets J3. Clin Pharmacol Drug Dev. 2016 Mar;5(2):109-117. doi: 10.1002/cpdd.209. Epub 2015 Aug 24.
Inhaled, long-acting bronchodilators represent a cornerstone of maintenance treatment for chronic obstructive pulmonary disease (COPD). Aclidinium bromide/formoterol fumarate 400/12 μg fixed-dose combination (FDC) has recently been licensed for use in adults with COPD in the European Union. This phase 1, randomized, open-label, 3-way, complete crossover, single-dose study assessed the pharmacokinetics, safety, and tolerability of an FDC, aclidinium bromide 400 μg, and formoterol fumarate 12 μg, all administered via Genuair™ to 30 healthy subjects. The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively. There were no major differences in relative bioavailability between the combination and monotherapies: the aclidinium Cmax and AUC0-t were 26% and 3% higher, respectively, with aclidinium/formoterol FDC compared with aclidinium alone, and 18% and 11% higher, respectively, compared with formoterol alone.
3.Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease.
Matera MG1, Sanduzzi A2, Cazzola M3. Int J Chron Obstruct Pulmon Dis. 2016 Jan 5;11:73-9. doi: 10.2147/COPD.S78000. eCollection 2016.
Co-administration of a long-acting β2-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β2-agonist fixed-dose combination that has been studied for this therapeutic indication.
4.Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
Crisafulli E1, Zanini A2, Pisi G3, Pignatti P4, Poli G5, Scuri M5, Chetta A1. Expert Rev Respir Med. 2016 May;10(5):481-90. doi: 10.1586/17476348.2016.1161508. Epub 2016 Mar 16.
Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the correct choice of device and proper inhalation technique, this influences drug delivery and distribution along the bronchial tree, including the most peripheral airways. The fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) is the only extrafine formulation available in pressurized metered dose inhaler (pMDI) and in dry powder inhaler (DPI). Here, we focus on the recent significant advances regarding BDP/FF fixed combination for the treatment of asthma.